Pipelines from BioNTech, Moderna and Defence Therapeutics: "It's a match!"

Curing cancer is a dream of humanity. However, when looking at mRNA projects from large companies such as BioNTech or Moderna, a higher survival rate is still considered a success. Moderna, together with the US pharmaceutical company Merck, Sharpe & Dohme (MSD), has now shown that an mRNA vaccine can reduce the mortality of seriously ill skin cancer patients by 40%. This article looks at how Moderna's project relates to Defence Therapeutics, where it connects to BioNTech's projects, and why adjuvant technology is critical in mRNA vaccines.

Den vollständigen Artikel lesen ...